Clinical Trial Update: A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AL002 in early Alzheimer's disease has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AL002

Snippet

Sponsor: Alector Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-10-29